Literature DB >> 20726384

Osteoarthritis: a review of treatment options.

Sheila M Seed1, Kaelen C Dunican, Ann M Lynch.   

Abstract

Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in the United States, especially among older adults. Treatment options have primarily focused on alleviating the pain often associated with this condition. Acetaminophen and nonsteroidal anti inflammatory drugs (NSAIDs) are often employed for relief of mild-to moderate pain associated with OA. NSAIDs are typically more effective than acetaminophen; however, because of adverse effects associated with long-term use of NSAIDS, acetaminophen is considered first-line therapy. Safety concerns of traditional pharmacotherapeutic agents used in the management of OA, such as NSAIDs and opioids, have led healthcare professionals to seek other options. Trials of disease modulating agents that focus on preventing further damage to the joints have the potential to change how this disease state is managed. This article reviews nonpharmacologic and pharmacologic approaches to management of OA of the knee and hip.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20726384

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  20 in total

1.  Myrtol ameliorates cartilage lesions in an osteoarthritis rat model.

Authors:  Binbin Ying; Abudu Kelimujiang Maimaiti; Donghui Song; Songsong Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Glenohumeral osteoarthritis.

Authors:  Michael Thomas; Amit Bidwai; Amar Rangan; Jonathan L Rees; Peter Brownson; Duncan Tennent; Clare Connor; Rohit Kulkarni
Journal:  Shoulder Elbow       Date:  2016-04-25

Review 3.  Facet joint pain--advances in patient selection and treatment.

Authors:  Steven P Cohen; Julie H Y Huang; Chad Brummett
Journal:  Nat Rev Rheumatol       Date:  2012-11-20       Impact factor: 20.543

Review 4.  FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.

Authors:  Jason S Kim; Silvana Borges; Daniel J Clauw; Philip G Conaghan; David T Felson; Thomas R Fleming; Rachel Glaser; Elizabeth Hart; Marc Hochberg; Yura Kim; Virginia B Kraus; Larissa Lapteva; Xiaojuan Li; Sharmila Majumdar; Timothy E McAlindon; Ali Mobasheri; Tuhina Neogi; Frank W Roemer; Rebecca Rothwell; Robert Shibuya; Jeffrey Siegel; Lee S Simon; Kurt P Spindler; Nikolay P Nikolov
Journal:  Semin Arthritis Rheum       Date:  2022-07-14       Impact factor: 5.431

5.  Effects of Meditation on Symptoms of Knee Osteoarthritis.

Authors:  Terry Kit Selfe; Kim E Innes
Journal:  Altern Complement Ther       Date:  2013-06-18

Review 6.  Therapeutic Potential of Differentiated Mesenchymal Stem Cells for Treatment of Osteoarthritis.

Authors:  Onju Ham; Chang Youn Lee; Ran Kim; Jihyun Lee; Sekyung Oh; Min Young Lee; Jongmin Kim; Ki-Chul Hwang; Lee-So Maeng; Woochul Chang
Journal:  Int J Mol Sci       Date:  2015-07-02       Impact factor: 5.923

7.  Effect of preoperative neuromuscular training (NEMEX-TJR) on functional outcome after total knee replacement: an assessor-blinded randomized controlled trial.

Authors:  Erika O Huber; Ewa M Roos; André Meichtry; Rob A de Bie; Heike A Bischoff-Ferrari
Journal:  BMC Musculoskelet Disord       Date:  2015-04-25       Impact factor: 2.362

8.  Pain treatment in arthritis-related pain: beyond NSAIDs.

Authors:  Mart van Laar; Joseph V Pergolizzi; Hans-Ulrich Mellinghoff; Ignacio Morón Merchante; Srinivas Nalamachu; Joanne O'Brien; Serge Perrot; Robert B Raffa
Journal:  Open Rheumatol J       Date:  2012-12-13

9.  A reliable protocol for the isolation of viable, chondrogenically differentiated human mesenchymal stem cells from high-density pellet cultures.

Authors:  Mujib Ullah; Houda Hamouda; Stefan Stich; Michael Sittinger; Jochen Ringe
Journal:  Biores Open Access       Date:  2012-12

10.  Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.

Authors:  Ilona Steigerwald; Michael Schenk; Uwe Lahne; Peter Gebuhr; Dietmar Falke; Barbara Hoggart
Journal:  Clin Drug Investig       Date:  2013-09       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.